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E-mail address: sspiegel@vcu.edu (S. Spiegel).In MKN1 gastric cancer cells, lysophosphatidic acid (LPA) upregulates expression of sphingosine
kinase 1 (SphK1) and its downregulation or inhibition suppresses LPA mediated proliferation.
Although LPA activates numerous signaling pathways downstream of its receptors, including extra-
cellular-signal-regulated kinase 1/2, p38, JNK, and Akt, and the transactivation of the epidermal
growth factor receptor, pharmacological and molecular approaches demonstrated that only activa-
tion of ERK1, in addition to the CCAAT/enhancer-binding protein b transcription factor, is involved
in transcriptional upregulation of SphK1 by LPA. Our data implicate ERK1 as an important mediator
of LPA signaling leading to upregulation of SphK1 and point to SphK1 and sphingosine-1-phosphate
production as potential therapeutic targets in gastric cancer.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lysophosphatidic acid (LPA) and sphingosine-1-phosphate
(S1P) and their respective families of G protein-coupled receptors
(GPCRs) have been implicated in progression of gastric cancer
[1,2], the second most common cause of cancer related deaths.
Binding of either of these lysophospholipids to their cognate recep-
tors on gastric cancer cells transactivates the epidermal growth
factor receptor (EGFR) [3,4], whose activation or overexpression
correlates with poor clinical outcomes [5]. Moreover, recent stud-
ies suggest that sphingosine kinase 1 (SphK1), one of the two iso-
enzymes that produce S1P, is up-regulated in gastric cancer lesions
and is associated with gastric cancer progression and poor survival
of patients [2]. In this regard, we have previously shown that LPA
markedly enhanced SphK1mRNA and protein in MKN1 gastric can-chemical Societies. Published by E
protein b; EGF, epidermal
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istry and Molecular Biology,
e, Richmond, VA 23298-0614,cer cells via activation of the LPA1 receptor [6], which may underlie
the metastatic behavior of gastric cancer [7]. Moreover, downreg-
ulation of SphK1 attenuated LPA-stimulated migration and inva-
sion of MNK1 cells, suggesting that SphK1 is a convergence point
of multiple cell surface receptors for three different ligands, LPA,
epidermal growth factor (EGF), and S1P, which have all been impli-
cated in regulation of motility and invasiveness of gastric cancer
cells [6].
In this study, we report that LPA-stimulated proliferation of
MKN1 gastric cancer cells also requires increased expression of
SphK1. We examined the signaling pathways responsible for tran-
scriptional upregulation of SphK1 by LPA and demonstrated that
activation of ERK1 and the transcription factor CCAAT enhancer-
binding protein b (C/EBPb) are critical to the proliferative response
of gastric cancer cells to LPA.
2. Materials and methods
2.1. Reagents
Ki16425 and recombinant EGF were purchased from Sigma–Al-
drich (St. Louis, MO). LPA was obtained from Avanti Polar Lipids
(Alabaster, AL). Antibodies against phospho-ERK1/2 (Thr202/
Tyr204), phospho-Akt (Ser473), Akt, ERK1, ERK2, phospho-C/EBPblsevier B.V. All rights reserved.
Fig. 1. LPA-induced proliferation of MKN1 cells requires SphK1. (A) MKN1 cells transfected with siControl or siSphK1 were stimulated without or with 10 lM LPA and cell
growth determined with WST-1 on the indicated days. (B) MKN1 cells were cultured in the absence or presence of LPA (10 lM) and 5 lM SK1-I and cell growth determined
with WST-1 on the indicated days. (C) Cells were cultured for 5 days in the absence or presence of LPA (10 lM) without or with 1, 3, 5, and 10 lM SK1-I and proliferation
determined by crystal violet staining. Data are expressed as fold ± SD of triplicate determinations. *P < 0.05, compared to LPA treated cells.
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Anti-C/EBPb antibody was from Santa Cruz Biotech (Santa Cruz,
CA).
2.2. Cell culture and transfection
The MKN1 human gastric cancer cell line was obtained from the
Riken Cell Bank (Tsukuba, Japan). Cells were cultured and transfec-
ted with small interfering RNA (siRNA) exactly as previously
described [6].
2.3. Proliferation assays
Cell proliferation was monitored with WST reagent (Roche
Applied Science, Indianapolis, IN). Cells were incubated with 2%
WST in serum-free DMEM without phenol red for 30 min.
Absorbance was measured at 450 nm with background subtraction
at 630 nm with a plate reader. Alternatively, cell proliferation was
quantiﬁed with 5% crystal violet (Fisher, Middletown, VA) and
absorbance was measured at 570 nm.
2.4. Quantitative real-time PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) and
reverse-transcribed with the high-capacity cDNA Archive Kit
(Applied Biosystems, Foster, CA). Quantitative real-time polymer-
ase chain reaction (QPCR) was performed with an ABI PRISM
7900HT (Applied Biosystems) as described [6].
2.5. Western blotting
Equal amounts of proteins were separated by SDS–PAGE and
transferred onto nitrocellulose membranes. Immunoreactive
signals were visualized by enhanced chemiluminescence using
SuperSignal West Pico Chemiluminescent Substrate (Pierce/Ther-
mo Fisher, Rockford, IL) [6].
2.6. Statistical analysis
Experiments were repeated at least three times with consistent
results. Results were analyzed for statistical signiﬁcance with theStudent’s t test for unpaired samples and P < 0.05 was considered
signiﬁcant.
3. Results and discussion
3.1. LPA stimulates proliferation of MKN1 cells
We have previously shown in gastric cancer cells that LPA
markedly stimulated expression of SphK1 [6], which has been
linked to proliferation and is up-regulated in many cancers, includ-
ing gastric cancer [2,8]. Therefore, it was of interest to examine the
role of SphK1 expression in LPA-induced proliferation of MKN1
cells. In agreement with previous studies [9], LPA-stimulated
growth of MKN1 cells (Fig. 1A). Downregulation of SphK1 in
MKN1 cells by transfection with siRNA, which decreased its
expression by 70% or more (data not shown), reduced the stimula-
tory effect on proliferation of LPA by more than 60% without signif-
icantly affecting the basal growth rate (Fig. 1A). A pharmacological
approach was next used to substantiate the involvement of SphK1.
Treatment with the isozyme-speciﬁc SphK1 inhibitor, SK1-I
[10,11], also suppressed LPA-induced proliferation in a time-
(Fig. 1B) and dose-dependent manner (Fig. 1C). These results sup-
port the notion that SphK1 is critical for LPA-induced gastric cancer
cell proliferation.
3.2. LPA signaling pathways involved in upregulation of SphK1
MKN1 cells express LPA1, LPA2, and LPA3 receptors [7], of which
the LPA1 receptor has been suggested to play a major role in LPA-
induced proliferation [12]. In agreement, we have previously
shown that an LPA1 receptor antagonist or downregulation of its
expression prevented SphK1 upregulation by LPA in MKN1 cells
[6]. Furthermore, enhanced SphK1 expression by LPA was also ob-
served in other types of human cancer cells and was strictly depen-
dent on the presence of the LPA1 receptor [6]. Taken together, our
results suggest that upregulation of SphK1 via activation of LPA1 is
a critical event in LPA mediated proliferation.
Therefore, it was of interest to examine which of the signaling
pathways downstream of LPA1 is involved in regulating expression
of SphK1. In agreement with previous studies [13,14], LPA rapidly
activated several members of the MAPK pathway, including
Fig. 2. Effects of inhibitors of LPA signaling pathways on SphK1 upregulation. (A) MKN1 cells were stimulated with 1 lM LPA for the indicated times, equal amounts of cell
lysates were separated by SDS–PAGE and analyzed by immunoblotting with the indicated antibodies. Blots were stripped and immunoblotted with anti-ERK2, anti-Akt, and
anti-tubulin to ensure equal loading and transfer. (B) MKN1 cells were pretreated with vehicle or with Ki16425 (10 lM), AG1478 (1 lM), Go6983 (10 lM), SB202190 (1 lM),
SP600125 (10 lM), BAY11-7082 (1 lM), CAY10470 (1 lM), LY294002 (10 lM), PX-866 (100 nM), Akt VIII (10 lM), U0126 (10 lM), or PD184352 (10 lM), for 1 h, and
subsequently stimulated with LPA (10 lM) for 6 h. RNA was isolated, reverse-transcribed, and SphK1 mRNA measured by QPCR. Data are expressed as fold induction after
normalization to GAPDH. *P < 0.001, #P < 0.05 compared to LPA treated cells. (C) Cultures were pretreated with the indicated inhibitors for 1 h prior to stimulation with LPA
(10 lM) for 20 min. Equal amounts of lysate proteins were analyzed by immunoblotting with anti-phospho-Akt and anti-phospho-ERK1/2 antibodies. Blots were stripped and
reprobed with anti-calnexin antibody to ensure equal loading and transfer.
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p38, as well as Akt, determined by western blotting with phos-
pho-speciﬁc antibodies (Fig. 2A). In contrast, the NF-jB pathway
was not activated, as shown by the lack of reduction in levels of
IkBa after treatment with LPA.
We next examined the effects of a variety of inhibitors that per-
turb LPA-stimulated signaling pathways on SphK1 expression.
Consistent with our previous results [6], both Ki16425, a LPA1
receptor antagonist, and the EGFR tyrosine kinase inhibitor
AG1478 prevented the increase in SphK1 expression induced by
LPA (Fig. 2B). However, upregulation of SphK1 by LPA was not
blocked by Go6983, a broad-spectrum protein kinase C inhibitor,
SB202190, a selective p38 inhibitor, or SP600125, a JNK inhibitor
(Fig. 2B). Similarly, BAY11-7082 and CAY10470, established NF-
jB inhibitors, had no effect on LPA-induced SphK1 upregulation
(Fig. 2B). LY294002, an inhibitor of PI3K, slightly inhibited LPA-
stimulated expression of SphK1. This is likely due to non-speciﬁc
effects of LY294002 [15], as PX-866, an irreversible and potent
PI3K inhibitor that reduced Akt activation by LPA to a similarextent (Fig. 2C), had no effect on SphK1 upregulation (Fig. 2B).
Moreover, Akt VIII, a potent and selective Akt1/2 inhibitor, which
completely blocked LPA-induced Akt activation (Fig. 2C), did not
decrease LPA-induced upregulation of SphK1 (Fig. 2B). Importantly,
both U0126, a highly selective inhibitor of MEK1 and MEK2, and
PD184352, a selective and non-competitive inhibitor of MEK1,
completely abolished the increase in SphK1 expression (Fig. 2B)
and as expected, drastically blocked LPA-induced ERK1/2 phos-
phorylation without affecting Akt phosphorylation (Fig. 2C).
3.3. ERK1 is critical for LPA-induced expression of SphK1
To unequivocally determine if Akt activation by LPA is involved
in SphK1 upregulation in MKN1 cells, its expression was down-
regulated. MKN1 cells express Akt isoforms 1, 2, and 3. Speciﬁc
siRNA mediated knockdown of each of these isoforms achieved
greater than 80% reduction in their mRNA levels (Fig. 3A),
although siRNA targeted to Akt3 also reduced expression of the
major isoform, Akt1. Nevertheless, downregulation of any of the
Fig. 3. ERK1 is important for upregulation of SphK1 by LPA. (A) MKN1 cells were transfected with ON TARGET plus SMART pool siRNA targeted to Akt1, Akt2, Akt3 or with
control siRNA. RNA was isolated and mRNA levels were measured by QPCR. (B) Duplicate cultures were stimulated for 6 h without or with LPA and SphK1 mRNAmeasured by
QPCR. (C,D) MKN1 cells were transfected with ON TARGET plus SMART pool siRNA targeted to ERK1, ERK2 or control siRNA. (C) RNA was isolated and mRNA levels were
measured by QPCR. (D) Western blotting analysis of ERK1/2 expression. (E) Duplicate cultures were stimulated for 6 h without or with LPA and SphK1 mRNA measured by
QPCR. (A,B,C,E) Data are expressed as fold change after normalization to GAPDH. *P < 0.05, compared to LPA-stimulated siControl.
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tion of SphK1 expression (Fig. 3B). These results indicate that acti-
vation of Akt by LPA is not required for its effect on SphK1
induction.
To conclusively demonstrate the involvement of ERK1/2, as was
suggested by the effects of the MEK1/2 inhibitors (Fig. 2B), we used
siRNA to downregulate ERK1 and ERK2 individually. Transfection
with either siRNA targeted to ERK1 or ERK2 reduced the levels of
the respective mRNAs by greater than 85% without decreasing
the other isoform (Fig. 3C). Similarly, immunoblotting revealed
that protein levels of ERK1 or ERK2 were speciﬁcally and signiﬁ-
cantly reduced (Fig. 3D). Interestingly, however, only downregula-
tion of ERK1 but not ERK2 signiﬁcantly reduced upregulation of
SphK1 by LPA (Fig. 3E).
3.4. LPA induces transcriptional activation of SphK1 via C/EBPb
Pretreatment with actinomycin D, which halts new RNA syn-
thesis, completely blocked the LPA-induced upregulation of SphK1
expression (Fig. 4A), indicating that LPA increases SphK1 by stim-
ulation of its transcription rather than by increasing mRNA stabil-
ity. As the human sphk1 promoter region contains a binding site for
the transcription factor C/EBPb, which is known to be phosphory-
lated and activated by ERK [16,17], we examined its role in the reg-ulation of SphK1 expression by LPA. In agreement with previous
studies [13,14], in MKN1 cells, LPA-stimulated phosphorylation
of C/EBPb at Thr235 (Fig. 4B), which enhances its transcription
activity. A signiﬁcant increase C/EBPb phosphorylation was ob-
served within 10 min and was sustained for 2 h. Anti-C/EBPb anti-
body detected the 38 kDa liver activating protein (LAP) protein, the
major form of C/EBPb, which is a transcriptional activator, while
the 20 kDa liver inhibitory protein (LIP) was barely noticeable
(Fig. 4B). Moreover, overexpression of LIP, a dominant-negative,
truncated form of C/EBPb, completely suppressed LPA-induced
SphK1 upregulation (Fig. 4C), suggesting that C/EBPb is important
for regulation of SphK1 expression.
Because activation of C/EBPb in other cell types is downstream
of LPA-induced transactivation of EGFR [13,14], and we have previ-
ously shown that in MKN1 cells LPA transactivates EGFR which in
turn is required for increased expression of SphK1 ([6] and Fig. 2C),
we examined the role of EGFR transactivation in ERK1/2 activation
and subsequent phosphorylation of C/EBPb. Pretreatment with the
EGFR tyrosine kinase inhibitor AG1478 blocked LPA-stimulated
phosphorylation of ERK1 and attenuated phosphorylation of
ERK2 (Fig. 4D). Moreover, LPA-induced phosphorylation of C/EBPb
was also markedly reduced by AG1478 as well as by U0126
(Fig. 4E), conﬁrming that C/EBPb is downstream of EGFR transacti-
vation and ERK1 activation by LPA.
Fig. 4. Involvement of C/EPBb in LPA-induced transcriptional upregulation of SphK1. (A) MKN1 cells were pretreated for 1 h with actinomycin D (5 lg/ml) and then
stimulated for 6 h without or with LPA and SphK1 mRNAmeasured by QPCR. (B) Cells were stimulated with LPA for the indicated times and equal amounts of lysates analyzed
by immunoblotting with anti-phospho-C/EPBb (Thr235) antibody or with anti-C/EPBb antibody. The LAP and LIP subunits are indicated. (C) MKN1 cells transfected with
vector or LIP were stimulated without or with LPA for 6 h and SphK1mRNAmeasured by QPCR (insert: western blotting demonstrating LIP expression). (D,E) MKN1 cells were
pretreated for 30 min with vehicle, AG1478 (1 lM) (D,E), or U0126 (10 lM) (E), as indicated. Cells were then stimulated for 5 min with vehicle, LPA (10 lM), or EGF (10 ng/
ml) (D), or for the designated times (E), as indicated. Proteins were analyzed by immunoblotting with antibodies against phospho-ERK1/2, phospho-Akt, tubulin, phospho-C/
EPBb (Thr235), or ERK1/2.
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SphK1, which is critical for cell growth and survival, is overex-
pressed in many types of cancers yet very little is known about
its transcriptional regulation. Based solely on the effects of phar-
macological inhibitors, it has previously been reported that both
ERK1/2 and PI3K/Akt pathways are involved in regulation of sphk1
gene expression [18,19]. Here we have shown that although LPA
activates multiple downstream signaling pathways, transcriptional
upregulation of SphK1 is dependent solely on ERK1, which in turn
phosphorylates C/EBPb leading to its activation and regulation of
transcription of SphK1. Transactivation of the EGFR by LPA also
speciﬁcally contributes to ERK1 activation. While activation of
Akt by LPA was completely dependent on transactivation of EGFR,
Akt was dispensable for LPA-stimulated SphK1 upregulation.
Although the ERK1/2 pathway was also required for enhanced
transcription of sphk1 in response to other stimuli, different tran-
scription factors, particularly Sp1 and AP-2, have been implicated
[19,20]. Our results shed light on the regulation of SphK1 transcrip-
tion, which is highly expressed in gastric cancer and correlates
with poor prognosis [2], and provide further support for the notion
that SphK1 might be a useful therapeutic target.
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